Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach
A CME-certified Program



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Oklahoma Allergy and Asthma SocietyOklahoma CityOK Saturday
Apr 8, 2017 9:00 AM
View Agenda  Maryland Allergy and Asthma SocietyColumbiaMD Thursday
Apr 20, 2017 6:00 PM
View Agenda  Allergy, Asthma and Immunology Society of Georgia (AAISG)BraseltonGA Saturday
May 6, 2017 8:00 AM
View Agenda  Philadelphia Allergy SocietyPhiladelphiaPA Thursday
May 11, 2017 7:00 PM
View Agenda  Sacramento Valley Allergy SocietySacramentoCA Wednesday
May 17, 2017 6:00 PM
View Agenda  Alabama Dermatology Society (ADS) New YorkNY Saturday
May 27, 2017 11:00 AM
View Agenda  Michigan Allergy & Asthma SocietyDearbornMI Friday
Jun 9, 2017 6:00 PM
View Agenda  Florida Society of Dermatology and Dermatologic Surgery (FSDDS)HollywoodFL Saturday
Jun 17, 2017 2:45 PM
View Agenda  North Carolina Dermatology Association (NCDA)Hot SpringsVA Saturday
Jul 8, 2017 12:00 PM
View Agenda  Alabama Society of Allergy, Asthma and Immunology (ASAAI)BirminghamAL Saturday
Jan 20, 2018 11:00 AM


Presentation Slides

Click here to view the presentation slides from this CME-certified program. (coming soon)

Download (PDF) Click here to view the presentation slides from this CME-certified series held at select American College of Radiology (ACR) state chapter meetings.

Program Description

Although atopic dermatitis (AD) is 2 to 3 times more prevalent than psoriasis, there have not been significant improvements in the management of this serious condition for decades. Available treatments do not address the underlying pathophysiology and contribute to a vicious cycle of nonadherence and disease progression. Patients and providers are dissatisfied and frustrated with the poor efficacy of topical agents and adverse events associated with broad-spectrum immunosuppressants.

An improved understanding of AD pathogenesis has led to the development of new treatments that target the Th2-polarized immune system, which plays a key role in the symptoms of AD and progression of the atopic march to more severe skin disease and respiratory allergic conditions. A new proactive, evidence-based, immunologically founded treatment approach allows patients to be more in control of their disease and actively involved in its management.

This CME activity will help allergists and dermatologists become more familiar with new treatment options for AD, and will discuss how emerging biomarkers in AD have the potential to enhance individualization of therapy, by targeting a patient's specific biological signatures, and help predict and monitor therapeutic response. Clinicians will be provided with strategies to educate their patients, facilitate acceptance of therapies, promote self-management, achieve disease control and ultimately prevent patients from progressing along the atopic march.

Agenda

Welcome and Introductions
Pathophysiologic Pathways, the Atopic March, and the Promise of New Treatment Options
Importance of Early AD Diagnosis and Severity Assessment to Guide Appropriate Treatment
New Treatment Approaches – Achieving New Treatment Goals
Q&A Session and Closing Remarks

Target Audience

This activity is intended for dermatologists, dermatology nurse practitioners/physician assistants, allergists, and other clinicians involved in the management of atopic dermatitis (AD).


Educational Objectives


At the conclusion of this activity, participants should be able to demonstrate the ability to:
  • Recognize the importance of targeting the underlying pathophysiology of AD that is driven by abnormal type 2 immune responses
  • Summarize the role of type 2 immune response in the pathophysiology of AD and the atopic march
  • Recognize hallmark signs and symptoms of AD to ensure early diagnosis
  • Apply appropriate assessments to determine disease severity
  • Explain how emerging systemic treatments for AD can improve management of the disease and its comorbidities, while considering MOAs, safety and efficacy profiles, indications, and impacts on AD biomarkers and disease progression

Steering Committee


Joel M. Gelfand, MD, MSCE
Professor of Dermatology
Professor of Epidemiology
Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Read Biography 

Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Chair of Pediatrics
Director of Center for Pediatric Eosinophilic Disease
The Children's Hospital of Philadelphia
Perelman School of Medicine at Univ. of Pennsylvania
Philadelphia, PA

 Read Biography

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.


FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

SPECIAL SERVICES

Event staff will be glad to assist you with any specials needs.  Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.


Provided By

Jointly provided by the Potomac Center for Medical Education and Rockpointe


     

     

     

Supported By

This activity has been supported through an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.

Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.



Registration

  VenueCityStateDate
View Agenda  Oklahoma Allergy and Asthma SocietyOklahoma CityOK Saturday
Apr 8, 2017 9:00 AM
View Agenda  Maryland Allergy and Asthma SocietyColumbiaMD Thursday
Apr 20, 2017 6:00 PM
View Agenda  Allergy, Asthma and Immunology Society of Georgia (AAISG)BraseltonGA Saturday
May 6, 2017 8:00 AM
View Agenda  Philadelphia Allergy SocietyPhiladelphiaPA Thursday
May 11, 2017 7:00 PM
View Agenda  Sacramento Valley Allergy SocietySacramentoCA Wednesday
May 17, 2017 6:00 PM
View Agenda  Alabama Dermatology Society (ADS) New YorkNY Saturday
May 27, 2017 11:00 AM
View Agenda  Michigan Allergy & Asthma SocietyDearbornMI Friday
Jun 9, 2017 6:00 PM
View Agenda  Florida Society of Dermatology and Dermatologic Surgery (FSDDS)HollywoodFL Saturday
Jun 17, 2017 2:45 PM
View Agenda  North Carolina Dermatology Association (NCDA)Hot SpringsVA Saturday
Jul 8, 2017 12:00 PM
View Agenda  Alabama Society of Allergy, Asthma and Immunology (ASAAI)BirminghamAL Saturday
Jan 20, 2018 11:00 AM